ImmunoCellular completes enrollment of Phase II trial of ICT-107 in glioblastoma ImmunoCellular Therapeutics has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma. A total of 278 patients at 25 participating sites have been enrolled in this trial, which was initiated in January 2011.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Subscribe for More Information